<?xml version="1.0" encoding="UTF-8"?>
<COCHRANE_REVIEW TYPE="INTERVENTION" REVMAN_VERSION="5" ID="000000000000000000" VERSION_NO="2.0" STAGE="R" STATUS="A">
<COVER_SHEET>
<TITLE>Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta-analysis [Data only. When citing this record quote "Cochrane Database of Systematic Reviews 2019, Issue 9".]</TITLE>
<CONTACT>
<PERSON ID="14342" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anthony</FIRST_NAME>
<MIDDLE_INITIALS>K</MIDDLE_INITIALS>
<LAST_NAME>Akobeng</LAST_NAME>
<SUFFIX>MB ChB MD FRCPCH MRCP (UK)</SUFFIX>
<POSITION>Senior Attending Physician in Pediatric Gastroenterology</POSITION>
<EMAIL_1>aakobeng@sidra.org</EMAIL_1>
<EMAIL_2>akobeng@aol.com</EMAIL_2>
<ADDRESS>
<ORGANISATION>Sidra Medicine</ORGANISATION>
<ADDRESS_1>PO Box 26999</ADDRESS_1>
<CITY>Doha</CITY>
<COUNTRY CODE="QA">Qatar</COUNTRY>
<PHONE_1>+974 4012 5850</PHONE_1>
<PHONE_2>+974 3003 6535</PHONE_2>
</ADDRESS>
</PERSON>
</CONTACT>
<CREATORS>
<PERSON ID="93470517078835916051111122125105" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Zipporah</FIRST_NAME>
<LAST_NAME>Iheozor-Ejiofor</LAST_NAME>
<SUFFIX>BSc, MPH</SUFFIX>
<POSITION>Research Project Lead</POSITION>
<EMAIL_1>ZIheozor-Ejiofor@uclan.ac.uk</EMAIL_1>
<EMAIL_2>zipporah.ejiofor@yahoo.com</EMAIL_2>
<MOBILE_PHONE>07979487498</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>School of Medicine</DEPARTMENT>
<ORGANISATION>University of Central Lancashire</ORGANISATION>
<ADDRESS_1>Harrington Building</ADDRESS_1>
<CITY>Preston</CITY>
<REGION>Lancashire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
</ADDRESS>
</PERSON>
<PERSON ID="15915590631813238153091106142200" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Morris</FIRST_NAME>
<LAST_NAME>Gordon</LAST_NAME>
<EMAIL_1>morris@betterprescribing.com</EMAIL_1>
<EMAIL_2>mgordon@uclan.ac.uk</EMAIL_2>
<ADDRESS>
<DEPARTMENT>School of Medicine</DEPARTMENT>
<ORGANISATION>University of Central Lancashire</ORGANISATION>
<CITY>Preston</CITY>
<REGION>Lancashire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
</ADDRESS>
</PERSON>
<PERSON ID="z1510141204285952117057276837283" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Andrew</FIRST_NAME>
<LAST_NAME>Clegg</LAST_NAME>
<POSITION>Professor of Health Services Research</POSITION>
<EMAIL_1>AClegg3@uclan.ac.uk</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Faculty of Health and Wellbeing</DEPARTMENT>
<ORGANISATION>University of Central Lancashire</ORGANISATION>
<ADDRESS_1>Brook Building</ADDRESS_1>
<ADDRESS_2>Victoria Street</ADDRESS_2>
<CITY>Preston</CITY>
<ZIP>PR1 2HE</ZIP>
<REGION>Lancashire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
</ADDRESS>
</PERSON>
<PERSON ID="z1803061513509586655562650562483" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Suzanne</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Freeman</LAST_NAME>
<EMAIL_1>scf20@le.ac.uk</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Department of Health Sciences</DEPARTMENT>
<ORGANISATION>University of Leicester</ORGANISATION>
<ADDRESS_1>University Road</ADDRESS_1>
<CITY>Leicester</CITY>
<ZIP>LE1 7RH</ZIP>
<COUNTRY CODE="GB">UK</COUNTRY>
</ADDRESS>
</PERSON>
<PERSON ID="z1803011016416476139383685360976" ROLE="AUTHOR">
<FIRST_NAME>Teuta</FIRST_NAME>
<LAST_NAME>Gjuladin-Hellon</LAST_NAME>
<EMAIL_1>thellon@uclan.ac.uk</EMAIL_1>
<MOBILE_PHONE>07501278722</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>School of Medicine</DEPARTMENT>
<ORGANISATION>University of Central Lancashire</ORGANISATION>
<CITY>Preston</CITY>
<ZIP>PR1 7BH</ZIP>
<REGION>Lancashire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>07501278722</PHONE_1>
</ADDRESS>
</PERSON>
<PERSON ID="9897" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>John</FIRST_NAME>
<MIDDLE_INITIALS>K</MIDDLE_INITIALS>
<LAST_NAME>MacDonald</LAST_NAME>
<EMAIL_1>jmacdon1@uwo.ca</EMAIL_1>
<EMAIL_2>john.macdonald@robartsinc.com</EMAIL_2>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Western Ontario</ORGANISATION>
<CITY>London</CITY>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
</ADDRESS>
</PERSON>
<PERSON ID="14342" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anthony</FIRST_NAME>
<MIDDLE_INITIALS>K</MIDDLE_INITIALS>
<LAST_NAME>Akobeng</LAST_NAME>
<SUFFIX>MB ChB MD FRCPCH MRCP (UK)</SUFFIX>
<POSITION>Senior Attending Physician in Pediatric Gastroenterology</POSITION>
<EMAIL_1>aakobeng@sidra.org</EMAIL_1>
<EMAIL_2>akobeng@aol.com</EMAIL_2>
<ADDRESS>
<ORGANISATION>Sidra Medicine</ORGANISATION>
<ADDRESS_1>PO Box 26999</ADDRESS_1>
<CITY>Doha</CITY>
<COUNTRY CODE="QA">Qatar</COUNTRY>
<PHONE_1>+974 4012 5850</PHONE_1>
<PHONE_2>+974 3003 6535</PHONE_2>
</ADDRESS>
</PERSON>
</CREATORS>
<DATES>
<UP_TO_DATE>
<DATE DAY="" MONTH="" YEAR="" />
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="" MONTH="" YEAR="" />
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR="" />
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR="" />
<REVIEW_PUBLISHED ISSUE="" YEAR="" />
<LAST_CITATION_ISSUE ISSUE="" YEAR="" />
</DATES>
<WHATS_NEW />
<HISTORY />
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES />
<EXTERNAL_SOURCES />
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO" />
<KEYWORDS />
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Interventions for maintaining surgically included remission in Crohn's disease</TITLE>
<SUMMARY_BODY>
<P><B>What is the aim of this review?</B></P>
<P>The aim of this Cochrane Review was to find out which drugs are most effective for maintaining remission in people with Crohn's disease who have undergone surgery to achieve remission. We collected and analysed all relevant studies to answer this question. We examined these studies using a method known as network meta-analysis (NMA) in order to compare and rank all the treatments in terms of clinical relapse, endoscopic relapse and safety.</P>
<P><B>What was studied in the review?</B></P>
<P>Crohn's disease is a chronic disease of the gut. It is known to change from periods when people experience a flare-up of the disease (relapse) to periods of good health (remission). Symptoms include abdominal pain, diarrhoea and weight loss. People with Crohn's disease may undergo surgery to remove diseased parts of their gut and achieve remission. However, their symptoms return after a while. Different drugs can be given to ensure that people with Crohn's disease remain in remission for as long as possible. These drugs include mesalazine, antibiotics, corticosteroids, and adalimumab, amongst others. Whilst these drugs have been known to reduce inflammation (pain and swelling) in the gut, side effects can occur with their use. We attempted to find out which treatments are the safest and most effective for maintaining remission in people with Crohn's disease after surgery.</P>
<P><B>How up-to-date is the review?</B></P>
<P>We searched for studies published up to 15 January 2019.</P>
<P><B>What are the main results of the review?</B></P>
<P>We included 35 relevant trials, which were published between 1976 and 2018. The studies included a total of 3249 participants who were mostly adults. Our NMA included 26 studies (2581 participants) and compared nine groups of treatments such as 5-aminosalicylic acid, adalimumab, antibiotics, budesonide, infliximab, probiotics, purine analogues, sulfasalazine, and a combination of sulfasalazine and prednisolone, which are used in preventing relapse after surgery in people with Crohn's disease. Adalimumab may reduce the chance of clinical relapse compared with placebo (dummy treatment). 5-aminosalicylic acid probably reduces the chance of clinical relapse compared with placebo. Budesonide may not be effective in preventing clinical relapse. The entire network evidence is of low certainty due to the small number of participants included in the studies and high risk of bias. This means that are confidence in these results is limited. Research to understand the effect of the treatments on endoscopic relapse and safety was limited, however cases of pancreatitis and leukopenia were reported in participants who received purine analogues.</P>
<P><B>Key messages</B></P>
<P>We uncertain about which treatments are most effective in preventing postoperative relapse in Crohn's disease. Alhough there is limited research on the harms (side effects) of these treatments, there were reported instances of pancreatitis and leukopenia in participants who received purine analogues.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P />
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P />
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P />
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P />
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P />
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P />
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P />
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P />
<CONDITION>
<P />
</CONDITION>
<INTERVENTION>
<P />
</INTERVENTION>
<THEORY>
<P />
</THEORY>
<IMPORTANCE>
<P />
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P />
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P />
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P />
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P />
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P />
<CRIT_OUTCOMES_PRIMARY>
<P />
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY>
<P />
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P />
<ELECTRONIC_SEARCHES>
<P />
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES>
<P />
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P />
<STUDY_SELECTION>
<P />
</STUDY_SELECTION>
<DATA_EXTRACTION>
<P />
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT>
<P />
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES>
<P />
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS>
<P />
</UNIT_OF_ANALYSIS>
<MISSING_DATA>
<P />
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT>
<P />
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT>
<P />
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS>
<P />
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS>
<P />
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS>
<P />
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P />
<SEARCH_RESULTS>
<P />
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR>
<P />
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR>
<P />
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P />
<ALLOCATION>
<P />
</ALLOCATION>
<BLINDING>
<P />
</BLINDING>
<EXCLUSIONS>
<P />
</EXCLUSIONS>
<SELECTIVE_REPORTING>
<P />
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES>
<P />
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P />
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P />
<SUMMARY_OF_RESULTS>
<P />
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS>
<P />
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE>
<P />
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES>
<P />
</POTENTIAL_BIASES>
<AGREEMENT>
<P />
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P />
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P />
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P />
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P />
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P />
</CONTRIBUTIONS>
<PRO_REV_DIFF>
<P />
</PRO_REV_DIFF>
<PUBLIC_NOTES>
<P />
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ardizzone-2004" NAME="Ardizzone 2004" YEAR="2004">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Armuzzi-2013" NAME="Armuzzi 2013" YEAR="2015">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergman-1976" NAME="Bergman 1976" YEAR="1976">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brignola-1995" NAME="Brignola 1995" YEAR="1995">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caprilli-1994" NAME="Caprilli 1994" YEAR="1994">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caprilli-2003" NAME="Caprilli 2003" YEAR="2003">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chermesh-2007" NAME="Chermesh 2007" YEAR="2007">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Haens-2008" NAME="D'Haens 2008" YEAR="2008">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ewe-1989" NAME="Ewe 1989" YEAR="1989">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ewe-1999" NAME="Ewe 1999" YEAR="1999">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fedorak-2015" NAME="Fedorak 2015" YEAR="2015">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Florent-1996" NAME="Florent 1996" YEAR="1996">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukushima-2018" NAME="Fukushima 2018" YEAR="2018">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gossum-2007" NAME="Gossum 2007" YEAR="2007">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanauer-2004" NAME="Hanauer 2004" YEAR="2004">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hellers-1999" NAME="Hellers 1999" YEAR="1999">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herfarth-2006" NAME="Herfarth 2006" YEAR="October 2006">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herfarth-2013" NAME="Herfarth 2013" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lochs-2000" NAME="Lochs 2000" YEAR="2000">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-Sanroman-2017" NAME="Lopez Sanroman 2017" YEAR="2017">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma_x00f1_osa-2013" NAME="Mañosa 2013" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marteau-2006" NAME="Marteau 2006" YEAR="2006">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McLeod-1995" NAME="McLeod 1995" YEAR="1995">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mowat-2016" NAME="Mowat 2016" YEAR="2016">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prantera-2002" NAME="Prantera 2002" YEAR="2002">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Regueiro-2009" NAME="Regueiro 2009" YEAR="2011">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Regueiro-2016" NAME="Regueiro 2016" YEAR="2016">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reinisch-2010" NAME="Reinisch 2010" YEAR="2010">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rutgeerts-2005" NAME="Rutgeerts 2005" YEAR="2005">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Savarino-2013" NAME="Savarino 2013" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scapa-2015" NAME="Scapa 2015" YEAR="2015">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutherland-1997" NAME="Sutherland 1997" YEAR="1997">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tursi-2014" NAME="Tursi 2014" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wenckert-1978" NAME="Wenckert 1978" YEAR="1978">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshida-2012" NAME="Yoshida 2012" YEAR="2012">
<IDENTIFIERS />
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES />
<AWAITING_STUDIES />
<ONGOING_STUDIES />
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES />
<OTHER_VERSIONS_REFERENCES />
<PENDING_REFERENCES />
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Ardizzone-2004">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Armuzzi-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bergman-1976">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brignola-1995">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Caprilli-1994">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Caprilli-2003">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chermesh-2007">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-D_x0027_Haens-2008">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ewe-1989">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ewe-1999">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fedorak-2015">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Florent-1996">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fukushima-2018">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gossum-2007">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hanauer-2004">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hellers-1999">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Herfarth-2006">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Herfarth-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lochs-2000">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lopez-Sanroman-2017">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marteau-2006">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ma_x00f1_osa-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McLeod-1995">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mowat-2016">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Prantera-2002">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Regueiro-2009">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Regueiro-2016">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Reinisch-2010">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rutgeerts-2005">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Savarino-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Scapa-2015">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sutherland-1997">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tursi-2014">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wenckert-1978">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yoshida-2012">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS />
<SOF_TABLES />
<ADDITIONAL_TABLES />
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Direct evidence: 5-ASA versus placebo</NAME>
<DICH_OUTCOME CHI2="1.9512339946920423" CI_END="0.9762684610525668" CI_START="0.7167646097159956" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8365134084187645" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.010430740610208539" LOG_CI_START="-0.1446234461256358" LOG_EFFECT_SIZE="-0.07752709336792216" METHOD="MH" NO="1" P_CHI2="0.7447280769807154" P_Q="1.0" P_Z="0.0235336575305825" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="328" TOTAL_2="343" WEIGHT="99.99999999999999" Z="2.26465827994999">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.698923302890756" CI_START="0.4847171859268237" EFFECT_SIZE="0.9074675324675324" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.23017377328742467" LOG_CI_START="-0.31451158184342903" LOG_EFFECT_SIZE="-0.042168904278002184" ORDER="5" O_E="0.0" SE="0.31995087383985565" STUDY_ID="STD-Brignola-1995" TOTAL_1="44" TOTAL_2="43" VAR="0.10236856167088725" WEIGHT="6.069688741840261" />
<DICH_DATA CI_END="1.103993302203702" CI_START="0.46214418204732316" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="28" LOG_CI_END="0.04296643858811052" LOG_CI_START="-0.3352225099445865" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="6" O_E="0.0" SE="0.22215006043359373" STUDY_ID="STD-Caprilli-1994" TOTAL_1="55" TOTAL_2="55" VAR="0.049350649350649346" WEIGHT="12.59041804855176" />
<DICH_DATA CI_END="1.054200626162229" CI_START="0.696920357774441" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.022923269836366094" LOG_CI_START="-0.15681684909759255" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="7" O_E="0.0" SE="0.1055802355897454" STUDY_ID="STD-Hanauer-2004" TOTAL_1="44" TOTAL_2="40" VAR="0.011147186147186142" WEIGHT="55.74010320523889" />
<DICH_DATA CI_END="1.2051174778364817" CI_START="0.6416803032800779" EFFECT_SIZE="0.8793748624257098" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="59" LOG_CI_END="0.0810293850762584" LOG_CI_START="-0.19268129140549017" LOG_EFFECT_SIZE="-0.05582595316461589" ORDER="8" O_E="0.0" SE="0.1607790062550791" STUDY_ID="STD-Lochs-2000" TOTAL_1="154" TOTAL_2="170" VAR="0.025849888852370766" WEIGHT="24.036672259624805" />
<DICH_DATA CI_END="1.4568081546431646" CI_START="0.12304752217617021" EFFECT_SIZE="0.42338709677419356" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1634023638045848" LOG_CI_START="-0.909927127317141" LOG_EFFECT_SIZE="-0.3732623817562782" ORDER="9" O_E="0.0" SE="0.6304790561515708" STUDY_ID="STD-Sutherland-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.3975038402457757" WEIGHT="1.5631177447442732" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6277952057866386" CI_END="3.43294791829797" CI_START="0.8059628218486423" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6633786073804286" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5356672147373216" LOG_CI_START="-0.09368499124500955" LOG_EFFECT_SIZE="0.220991111746156" METHOD="MH" NO="2" P_CHI2="0.890040855982701" P_Q="1.0" P_Z="0.16868363736563902" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="199" WEIGHT="100.0" Z="1.376445862296993">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.398709180953243" CI_START="0.41460705261980624" EFFECT_SIZE="1.628787878787879" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8060923720885527" LOG_CI_START="-0.38236331466904167" LOG_EFFECT_SIZE="0.2118645287097555" ORDER="10" O_E="0.0" SE="0.6981047533519394" STUDY_ID="STD-Brignola-1995" TOTAL_1="44" TOTAL_2="43" VAR="0.48735024665257226" WEIGHT="28.044616435237877" />
<DICH_DATA CI_END="101.81163541914079" CI_START="0.24555150201722367" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0077974136546413" LOG_CI_START="-0.6098574049826039" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11" O_E="0.0" SE="1.5376233980678475" STUDY_ID="STD-Caprilli-1994" TOTAL_1="55" TOTAL_2="55" VAR="2.3642857142857143" WEIGHT="4.620987935351696" />
<DICH_DATA CI_END="6.267451613822783" CI_START="0.3903367719084859" EFFECT_SIZE="1.564102564102564" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7970909897892678" LOG_CI_START="-0.4085605338207322" LOG_EFFECT_SIZE="0.19426522798426782" ORDER="123" O_E="0.0" SE="0.7082056730398077" STUDY_ID="STD-Florent-1996" TOTAL_1="65" TOTAL_2="61" VAR="0.501555275325767" WEIGHT="28.606115790272405" />
<DICH_DATA CI_END="4.484578579593015" CI_START="0.41464411855620964" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6517216382036651" LOG_CI_START="-0.3823244904087528" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="12" O_E="0.0" SE="0.6074038145578228" STUDY_ID="STD-Hanauer-2004" TOTAL_1="44" TOTAL_2="40" VAR="0.3689393939393939" WEIGHT="38.728279839138025" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1208077697729226" CI_END="1.8733588262920555" CI_START="0.3366309922680009" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7941225601685877" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="10.778634216409694" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.2726209708365708" LOG_CI_START="-0.4728459027649429" LOG_EFFECT_SIZE="-0.10011246596418608" METHOD="MH" NO="3" P_CHI2="0.2897446237277914" P_Q="1.0" P_Z="0.5985917807995569" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="198" TOTAL_2="210" WEIGHT="100.0" Z="0.5264266854550633">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6847560641029866" CI_START="0.009011434595382995" EFFECT_SIZE="0.18222222222222223" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5664087422573171" LOG_CI_START="-2.045206065040571" LOG_EFFECT_SIZE="-0.739398661391627" ORDER="17" O_E="0.0" SE="1.5340754655085709" STUDY_ID="STD-Hanauer-2004" TOTAL_1="44" TOTAL_2="40" VAR="2.3533875338753387" WEIGHT="23.418526656643923" />
<DICH_DATA CI_END="2.4797028044302984" CI_START="0.38828599199329084" EFFECT_SIZE="0.9812409812409812" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.39439963319303684" LOG_CI_START="-0.4108482770041777" LOG_EFFECT_SIZE="-0.008224321905570424" ORDER="18" O_E="0.0" SE="0.4730066084912854" STUDY_ID="STD-Lochs-2000" TOTAL_1="154" TOTAL_2="170" VAR="0.22373525167642813" WEIGHT="76.58147334335608" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6303834827665082" CI_END="3.9396412107712937" CI_START="0.7137352036682194" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6768603465851173" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5954566717551755" LOG_CI_START="-0.1464628819430862" LOG_EFFECT_SIZE="0.2244968949060446" METHOD="MH" NO="4" P_CHI2="0.7296490035228715" P_Q="1.0" P_Z="0.23557172193204912" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="156" WEIGHT="100.0" Z="1.18612813603204">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="101.81163541914079" CI_START="0.24555150201722367" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0077974136546413" LOG_CI_START="-0.6098574049826039" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="21" O_E="0.0" SE="1.5376233980678475" STUDY_ID="STD-Caprilli-1994" TOTAL_1="55" TOTAL_2="55" VAR="2.3642857142857143" WEIGHT="6.422018348623853" />
<DICH_DATA CI_END="6.267451613822783" CI_START="0.3903367719084859" EFFECT_SIZE="1.564102564102564" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7970909897892678" LOG_CI_START="-0.4085605338207322" LOG_EFFECT_SIZE="0.19426522798426782" ORDER="124" O_E="0.0" SE="0.7082056730398077" STUDY_ID="STD-Florent-1996" TOTAL_1="65" TOTAL_2="61" VAR="0.501555275325767" WEIGHT="39.75535168195719" />
<DICH_DATA CI_END="4.484578579593015" CI_START="0.41464411855620964" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6517216382036651" LOG_CI_START="-0.3823244904087528" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="22" O_E="0.0" SE="0.6074038145578228" STUDY_ID="STD-Hanauer-2004" TOTAL_1="44" TOTAL_2="40" VAR="0.3689393939393939" WEIGHT="53.82262996941896" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1376939092864977" CI_END="1.154610699595291" CI_START="0.9470793876152693" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.045709325915546" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="174" I2="53.22061799138624" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.06243557771974276" LOG_CI_START="-0.02361361533866541" LOG_EFFECT_SIZE="0.01941098119053867" METHOD="MH" NO="5" P_CHI2="0.1437178550018159" P_Q="1.0" P_Z="0.37655721104437156" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="219" TOTAL_2="231" WEIGHT="100.0" Z="0.8842575435243492">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1725162016245767" CI_START="0.6778932583627222" EFFECT_SIZE="0.8915384615384615" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="40" LOG_CI_END="0.06911885243406185" LOG_CI_START="-0.1688386851205434" LOG_EFFECT_SIZE="-0.049859916343240794" ORDER="218" O_E="0.0" SE="0.13977743546838312" STUDY_ID="STD-Florent-1996" TOTAL_1="65" TOTAL_2="61" VAR="0.019537731466118004" WEIGHT="24.470332336393867" />
<DICH_DATA CI_END="1.210946325059484" CI_START="0.9913458496707435" EFFECT_SIZE="1.0956580732700136" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="134" LOG_CI_END="0.08312489355833175" LOG_CI_START="-0.003774807270153651" LOG_EFFECT_SIZE="0.03967504314408905" ORDER="191" O_E="0.0" SE="0.05104531442710896" STUDY_ID="STD-Lochs-2000" TOTAL_1="154" TOTAL_2="170" VAR="0.002605624124962418" WEIGHT="75.52966766360613" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Direct evidence: 5-ASA versus adalimumab</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="56.40671656984072" CI_START="1.1346166536879971" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.751330820216405" LOG_CI_START="0.054849153767481895" LOG_EFFECT_SIZE="0.9030899869919435" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03691529299119185" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="2.0866996494079073">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="56.40671656984072" CI_START="1.134616653687997" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.751330820216405" LOG_CI_START="0.05484915376748181" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="25" O_E="0.0" SE="0.9965217285917832" STUDY_ID="STD-Savarino-2013" TOTAL_1="18" TOTAL_2="16" VAR="0.9930555555555556" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7088496048978163" CI_START="0.748965501360229" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1313131313131313" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="100.0" ID="CMP-002.02" LOG_CI_END="0.23270384233624" LOG_CI_START="-0.12553818619097662" LOG_EFFECT_SIZE="0.05358282807263168" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5576673226522453" Q="4.349228355064291E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="0.5863098399923289">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7088496048978163" CI_START="0.748965501360229" EFFECT_SIZE="1.1313131313131313" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.23270384233624" LOG_CI_START="-0.12553818619097662" LOG_EFFECT_SIZE="0.05358282807263168" ORDER="26" O_E="0.0" SE="0.2104331408835281" STUDY_ID="STD-Savarino-2013" TOTAL_1="18" TOTAL_2="16" VAR="0.044282106782106784" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="89.94575782951351" CI_START="1.9764998602240285" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.333333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.953980685250454" LOG_CI_START="0.2958967879661459" LOG_EFFECT_SIZE="1.1249387366083" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.007825607258665906" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="2.6595028299562564">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="89.94575782951351" CI_START="1.9764998602240285" EFFECT_SIZE="13.333333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" LOG_CI_END="1.953980685250454" LOG_CI_START="0.2958967879661459" LOG_EFFECT_SIZE="1.1249387366083" ORDER="192" O_E="0.0" SE="0.9739666889124654" STUDY_ID="STD-Savarino-2013" TOTAL_1="18" TOTAL_2="16" VAR="0.9486111111111111" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="61.58355000009518" CI_START="0.11699530393381599" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6842105263157894" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.789464720309532" LOG_CI_START="-0.931831570019317" LOG_EFFECT_SIZE="0.4288165751451074" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5367766604310871" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="0.6176946231434873">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="61.58355000009518" CI_START="0.11699530393381599" EFFECT_SIZE="2.6842105263157894" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.789464720309532" LOG_CI_START="-0.931831570019317" LOG_EFFECT_SIZE="0.4288165751451074" ORDER="27" O_E="0.0" SE="1.5985029115730547" STUDY_ID="STD-Savarino-2013" TOTAL_1="18" TOTAL_2="16" VAR="2.5552115583075334" WEIGHT="100.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Direct evidence: 5-ASA versus purine analogues</NAME>
<DICH_OUTCOME CHI2="2.4112190543214567" CI_END="1.114922596146222" CI_START="0.8063595899316814" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9481711488091341" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="112" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.047244717399022626" LOG_CI_START="-0.09347124467511937" LOG_EFFECT_SIZE="-0.023113263638048383" METHOD="MH" NO="1" P_CHI2="0.4915498163009918" P_Q="1.0" P_Z="0.519661851178363" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="177" WEIGHT="100.0" Z="0.6438667458619267">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2957471681899524" CI_START="0.6451245951898509" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.11252026837722856" LOG_CI_START="-0.19035640043796795" LOG_EFFECT_SIZE="-0.03891806603036967" ORDER="2" O_E="0.0" SE="0.17791125452573686" STUDY_ID="STD-Ardizzone-2004" TOTAL_1="71" TOTAL_2="71" VAR="0.03165241448692152" WEIGHT="32.05148619078567" />
<DICH_DATA CI_END="1.4281393231347825" CI_START="0.8496649603784701" EFFECT_SIZE="1.1015625" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="32" LOG_CI_END="0.15477057741013248" LOG_CI_START="-0.07075229139510938" LOG_EFFECT_SIZE="0.04200914300751153" ORDER="183" O_E="0.0" SE="0.13247324949240402" STUDY_ID="STD-Hanauer-2004" TOTAL_1="44" TOTAL_2="47" VAR="0.017549161831076725" WEIGHT="28.338142892700926" />
<DICH_DATA CI_END="1.1946697280114786" CI_START="0.7220161668385097" EFFECT_SIZE="0.9287469287469288" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="33" LOG_CI_END="0.07724785915278194" LOG_CI_START="-0.14145307792877135" LOG_EFFECT_SIZE="-0.03210260938799469" ORDER="107" O_E="0.0" SE="0.1284660130288027" STUDY_ID="STD-Herfarth-2006" TOTAL_1="37" TOTAL_2="42" VAR="0.016503516503516502" WEIGHT="28.307316194538377" />
<DICH_DATA CI_END="1.2333665364766515" CI_START="0.4068021113532209" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.09109216103475856" LOG_CI_START="-0.39061680170142266" LOG_EFFECT_SIZE="-0.14976232033333206" ORDER="28" O_E="0.0" SE="0.2829582292090551" STUDY_ID="STD-Savarino-2013" TOTAL_1="18" TOTAL_2="17" VAR="0.08006535947712416" WEIGHT="11.303054721975029" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2962521550538604" CI_END="1.3635952375086973" CI_START="0.8720353650282103" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0904601187992278" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" I2="8.98754528228802" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.13468547574304834" LOG_CI_START="-0.05946590207985904" LOG_EFFECT_SIZE="0.03760978683159464" METHOD="MH" NO="2" P_CHI2="0.34816468168875403" P_Q="1.0" P_Z="0.44764689730884666" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="177" WEIGHT="100.0" Z="0.7593438530566743">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4668431396395785" CI_START="0.9120969079244899" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" LOG_CI_END="0.3921415346722174" LOG_CI_START="-0.03995901656085485" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="3" O_E="0.0" SE="0.2538180027265315" STUDY_ID="STD-Ardizzone-2004" TOTAL_1="71" TOTAL_2="71" VAR="0.06442357850808555" WEIGHT="26.366729043868343" />
<DICH_DATA CI_END="1.8370091907798956" CI_START="0.2760555708149124" EFFECT_SIZE="0.7121212121212122" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.26411132913923674" LOG_CI_START="-0.5590034843515392" LOG_EFFECT_SIZE="-0.1474460776061512" ORDER="184" O_E="0.0" SE="0.48350171592852104" STUDY_ID="STD-Hanauer-2004" TOTAL_1="44" TOTAL_2="47" VAR="0.23377390930582423" WEIGHT="12.748748109123154" />
<DICH_DATA CI_END="1.3620256857215902" CI_START="0.760432263954788" EFFECT_SIZE="1.0177073625349486" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="0.1341852977837891" LOG_CI_START="-0.11893946497825447" LOG_EFFECT_SIZE="0.0076229164027673026" ORDER="406" O_E="0.0" SE="0.148686738634208" STUDY_ID="STD-Herfarth-2006" TOTAL_1="37" TOTAL_2="42" VAR="0.02210774624567728" WEIGHT="39.79113961191383" />
<DICH_DATA CI_END="1.3146811866397183" CI_START="0.6784727108796884" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.11882044813370284" LOG_CI_START="-0.16846761558376713" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="29" O_E="0.0" SE="0.1687544307264926" STUDY_ID="STD-Savarino-2013" TOTAL_1="18" TOTAL_2="17" VAR="0.02847805788982259" WEIGHT="21.093383235094674" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.425888060319718" CI_END="4.074583535825083" CI_START="0.83353897594211" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8429118773946358" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="58.77798253113931" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.6100832259996646" LOG_CI_START="-0.07907408792856312" LOG_EFFECT_SIZE="0.26550456903555075" METHOD="MH" NO="3" P_CHI2="0.11934580193646838" P_Q="1.0" P_Z="0.13099483776193893" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="118" WEIGHT="100.0" Z="1.5101904384481448">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mesalamine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mesalamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.074245312048556" CI_START="1.0289344073086457" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.783492327180157" LOG_CI_START="0.012387690163918198" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="1" O_E="0.0" SE="0.45295068081285217" STUDY_ID="STD-Ardizzone-2004" TOTAL_1="71" TOTAL_2="71" VAR="0.20516431924882628" WEIGHT="71.26436781609195" />
<DICH_DATA CI_END="4.323670096918947" CI_START="0.010526036929492468" EFFECT_SIZE="0.21333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6358525491680473" LOG_CI_START="-1.9777351106395977" LOG_EFFECT_SIZE="-0.6709412807357752" ORDER="185" O_E="0.0" SE="1.5352343288385797" STUDY_ID="STD-Hanauer-2004" TOTAL_1="44" TOTAL_2="47" VAR="2.3569444444444443" WEIGHT="28.735632183908045" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9808598658633322" CI_END="0.9238432061817384" CI_START="0.3070590331535566" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5326109289862971" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.034401730585331296" LOG_CI_START="-0.5127781218902204" LOG_EFFECT_SIZE="-0.27358992623777584" METHOD="MH" NO="4" P_CHI2="0.8058831789538228" P_Q="1.0" P_Z="0.024970434482071452" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="177" WEIGHT="100.0" Z="2.2418598062346744">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.971879249927769" CI_START="0.16462950516938332" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.012387690163918143" LOG_CI_START="-0.783492327180157" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="30" O_E="0.0" SE="0.45295068081285217" STUDY_ID="STD-Ardizzone-2004" TOTAL_1="71" TOTAL_2="71" VAR="0.20516431924882628" WEIGHT="47.1686257727169" />
<DICH_DATA CI_END="1.8370091907798956" CI_START="0.2760555708149124" EFFECT_SIZE="0.7121212121212122" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.26411132913923674" LOG_CI_START="-0.5590034843515392" LOG_EFFECT_SIZE="-0.1474460776061512" ORDER="186" O_E="0.0" SE="0.48350171592852104" STUDY_ID="STD-Hanauer-2004" TOTAL_1="44" TOTAL_2="47" VAR="0.23377390930582423" WEIGHT="27.368169679114857" />
<DICH_DATA CI_END="2.040862222731254" CI_START="0.20616044763210006" EFFECT_SIZE="0.6486486486486487" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.30981368677033605" LOG_CI_START="-0.685794651481114" LOG_EFFECT_SIZE="-0.18799048235538895" ORDER="108" O_E="0.0" SE="0.5848252662296594" STUDY_ID="STD-Herfarth-2006" TOTAL_1="37" TOTAL_2="42" VAR="0.342020592020592" WEIGHT="20.61885919853785" />
<DICH_DATA CI_END="7.259648833094586" CI_START="0.013736613709900562" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8609156133257376" LOG_CI_START="-1.8621203144641083" LOG_EFFECT_SIZE="-0.5006023505691853" ORDER="31" O_E="0.0" SE="1.5995247832289885" STUDY_ID="STD-Savarino-2013" TOTAL_1="18" TOTAL_2="17" VAR="2.5584795321637426" WEIGHT="4.844345349630384" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9354729011384817" CI_START="0.8569646060621656" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2878787878787878" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.2867870950719659" LOG_CI_START="-0.06703711472711785" LOG_EFFECT_SIZE="0.10987499017242405" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.22349889228089204" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="1.2172769277824649">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.935472901138482" CI_START="0.8569646060621656" EFFECT_SIZE="1.2878787878787878" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.286787095071966" LOG_CI_START="-0.06703711472711785" LOG_EFFECT_SIZE="0.10987499017242405" ORDER="193" O_E="0.0" SE="0.20783809229406752" STUDY_ID="STD-Savarino-2013" TOTAL_1="18" TOTAL_2="17" VAR="0.043196672608437334" WEIGHT="100.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Direct evidence: antibiotics versus placebo</NAME>
<DICH_OUTCOME CHI2="0.6536246289542926" CI_END="1.381749744562273" CI_START="0.6466817414366095" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9452789699570815" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.14042939296779464" LOG_CI_START="-0.18930940085166154" LOG_EFFECT_SIZE="-0.024440003941933474" METHOD="MH" NO="1" P_CHI2="0.4188200339107494" P_Q="1.0" P_Z="0.771401424401821" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="56" WEIGHT="99.99999999999999" Z="0.2905422619725744">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.211352715902981" CI_START="0.6258988152496171" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.34465801908400856" LOG_CI_START="-0.20349587051259402" LOG_EFFECT_SIZE="0.07058107428570728" ORDER="58" O_E="0.0" SE="0.3219883081545591" STUDY_ID="STD-Herfarth-2013" TOTAL_1="17" TOTAL_2="16" VAR="0.10367647058823531" WEIGHT="29.184549356223172" />
<DICH_DATA CI_END="1.3673056992032913" CI_START="0.5284114594278295" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.13586562402979901" LOG_CI_START="-0.27702777260121353" LOG_EFFECT_SIZE="-0.07058107428570728" ORDER="59" O_E="0.0" SE="0.242535625036333" STUDY_ID="STD-Rutgeerts-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.05882352941176471" WEIGHT="70.81545064377681" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1636047699387913" CI_START="0.021146287326569462" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1568627450980392" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.0658054928722458" LOG_CI_START="-1.6747658710842313" LOG_EFFECT_SIZE="-0.8044801891059928" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.07002268255229732" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="1.8117639179580856">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1636047699387913" CI_START="0.021146287326569462" EFFECT_SIZE="0.1568627450980392" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.0658054928722458" LOG_CI_START="-1.6747658710842313" LOG_EFFECT_SIZE="-0.8044801891059928" ORDER="58" O_E="0.0" SE="1.0224202351552427" STUDY_ID="STD-Herfarth-2013" TOTAL_1="17" TOTAL_2="16" VAR="1.045343137254902" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8876464830245145" CI_START="0.02932928506327155" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23529411764705882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.2759206632420559" LOG_CI_START="-1.5326985233426789" LOG_EFFECT_SIZE="-0.6283889300503115" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.17321533318285362" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="1.3619447148605905">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8876464830245145" CI_START="0.02932928506327155" EFFECT_SIZE="0.23529411764705882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2759206632420559" LOG_CI_START="-1.5326985233426789" LOG_EFFECT_SIZE="-0.6283889300503115" ORDER="58" O_E="0.0" SE="1.062391863009236" STUDY_ID="STD-Herfarth-2013" TOTAL_1="17" TOTAL_2="16" VAR="1.1286764705882353" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.25512586980388346" CI_END="1.0680905915475098" CI_START="0.675842526185477" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.849624060150376" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.028608089528362714" LOG_CI_START="-0.1701544844956949" LOG_EFFECT_SIZE="-0.07077319748366606" METHOD="MH" NO="4" P_CHI2="0.6134887364689332" P_Q="1.0" P_Z="0.16278528519797844" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="56" WEIGHT="100.0" Z="1.3957649604792992">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5241569982500396" CI_START="0.5811823518220062" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.1830297045113676" LOG_CI_START="-0.2356875819560659" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="202" O_E="0.0" SE="0.24595660675496628" STUDY_ID="STD-Herfarth-2013" TOTAL_1="17" TOTAL_2="16" VAR="0.06049465240641712" WEIGHT="25.56390977443609" />
<DICH_DATA CI_END="1.0591012523261178" CI_START="0.6320656180257049" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="33" LOG_CI_END="0.02493748156591203" LOG_CI_START="-0.1992378330037124" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="204" O_E="0.0" SE="0.1316816894639013" STUDY_ID="STD-Rutgeerts-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.017340067340067336" WEIGHT="74.43609022556392" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Direct evidence: budesonide versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1757738002429936" CI_START="0.39958406654852496" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6854345165238678" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.07032377858085112" LOG_CI_START="-0.39839183763328123" LOG_EFFECT_SIZE="-0.1640340295262151" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.17011408289886615" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="40" WEIGHT="99.99999999999999" Z="1.3718373315877916">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1757738002429936" CI_START="0.39958406654852496" EFFECT_SIZE="0.6854345165238678" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.07032377858085112" LOG_CI_START="-0.39839183763328123" LOG_EFFECT_SIZE="-0.1640340295262151" ORDER="64" O_E="0.0" SE="0.275325873143901" STUDY_ID="STD-Ewe-1999" TOTAL_1="43" TOTAL_2="40" VAR="0.07580433642245146" WEIGHT="99.99999999999999" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.604568272878142" CI_END="1.2728415067727261" CI_START="0.8192653983931555" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0211733467621948" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="58" I2="61.60592101143258" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.10477432901159311" LOG_CI_START="-0.08657538714506074" LOG_EFFECT_SIZE="0.009099470933266202" METHOD="MH" NO="2" P_CHI2="0.10655621799284876" P_Q="1.0" P_Z="0.8521241935194055" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="107" WEIGHT="100.0" Z="0.18640879815018904">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.890149270432207" CI_START="0.7671979433775556" EFFECT_SIZE="1.7275747508305648" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5899662661280844" LOG_CI_START="-0.11509257004617293" LOG_EFFECT_SIZE="0.2374368480409558" ORDER="64" O_E="0.0" SE="0.4141550504662854" STUDY_ID="STD-Ewe-1999" TOTAL_1="43" TOTAL_2="40" VAR="0.17152440582673142" WEIGHT="12.795568475747935" />
<DICH_DATA CI_END="1.1325140360395607" CI_START="0.7433441261884727" EFFECT_SIZE="0.9175225645813881" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="51" LOG_CI_END="0.05404359323387984" LOG_CI_START="-0.12881008596288815" LOG_EFFECT_SIZE="-0.03738324636450419" ORDER="130" O_E="0.0" SE="0.10740915630049144" STUDY_ID="STD-Hellers-1999" TOTAL_1="63" TOTAL_2="67" VAR="0.0115367268571834" WEIGHT="87.20443152425207" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0016346097315535417" CI_END="3.137626335596834" CI_START="0.35314378529604673" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.4966012215800776" LOG_CI_START="-0.452048432157773" LOG_EFFECT_SIZE="0.022276394711152208" METHOD="MH" NO="3" P_CHI2="0.9677500741735864" P_Q="1.0" P_Z="0.9266594344933" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="107" WEIGHT="100.0" Z="0.09204858962890028">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.439679023172555" CI_START="0.06476818582168423" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.188638267507881" LOG_CI_START="-1.188638267507881" LOG_EFFECT_SIZE="0.0" ORDER="64" O_E="0.0" SE="1.3964240043768943" STUDY_ID="STD-Ewe-1999" TOTAL_1="40" TOTAL_2="40" VAR="1.9500000000000002" WEIGHT="17.105263157894736" />
<DICH_DATA CI_END="3.4989764330380217" CI_START="0.32324177963342027" EFFECT_SIZE="1.0634920634920635" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5439410173511515" LOG_CI_START="-0.49047251085666205" LOG_EFFECT_SIZE="0.026734253247244728" ORDER="131" O_E="0.0" SE="0.6076196268988155" STUDY_ID="STD-Hellers-1999" TOTAL_1="63" TOTAL_2="67" VAR="0.3692016109926558" WEIGHT="82.89473684210526" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1236646288096444" CI_START="0.7987320257277576" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.050636710173725175" LOG_CI_START="-0.09759890187277105" LOG_EFFECT_SIZE="-0.023481095849522914" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5346445051088777" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.6209317929373458">
<NAME>Histologic relapse</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1236646288096444" CI_START="0.7987320257277577" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.050636710173725175" LOG_CI_START="-0.097598901872771" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="205" O_E="0.0" SE="0.08707433229422573" STUDY_ID="STD-Ewe-1999" TOTAL_1="43" TOTAL_2="43" VAR="0.007581939344485242" WEIGHT="100.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Direct evidence: infliximab versus adalimumab</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.867772482168174" CI_START="0.07210963413813187" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Tursi-2014" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-Tursi-2014" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="18.687408406451848" CI_START="0.21404787186108679" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="1.2715490770440219" LOG_CI_START="-0.6694890857160595" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5432337102222069" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6079302932701574">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="196" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Tursi-2014" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.136685127407792" CI_START="0.3152724212756815" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.8534965359826647" LOG_CI_START="-0.5013140178713021" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6104074515192484" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.5094919356210584">
<NAME>Histologic relapse</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.136685127407792" CI_START="0.3152724212756815" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8534965359826647" LOG_CI_START="-0.5013140178713021" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="195" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Tursi-2014" TOTAL_1="10" TOTAL_2="10" VAR="0.6333333333333333" WEIGHT="100.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Direct evidence: infliximab versus purine analogues</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.74517645387675" CI_START="0.05268507977100684" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.676252366714867" LOG_CI_START="-1.2783123580428295" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5460277483123641" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="0.6037231126646818">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.745176453876752" CI_START="0.05268507977100682" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6762523667148672" LOG_CI_START="-1.2783123580428297" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="281" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Armuzzi-2013" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.391737873352941" CI_START="0.015031798071690874" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.8687465574849318" LOG_CI_START="-1.8229890669242566" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.48716597433069375" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="0.6948234195283236">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.391737873352934" CI_START="0.015031798071690874" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8687465574849313" LOG_CI_START="-1.8229890669242566" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="282" O_E="0.0" SE="1.5811388300841895" STUDY_ID="STD-Armuzzi-2013" TOTAL_1="11" TOTAL_2="11" VAR="2.4999999999999996" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.052704911192013" CI_START="0.07116067734430037" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="1.1477599267279106" LOG_CI_START="-1.1477599267279106" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="0.0">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.052704911192018" CI_START="0.07116067734430034" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1477599267279106" LOG_CI_START="-1.1477599267279106" LOG_EFFECT_SIZE="0.0" ORDER="283" O_E="0.0" SE="1.3483997249264843" STUDY_ID="STD-Armuzzi-2013" TOTAL_1="11" TOTAL_2="11" VAR="1.8181818181818183" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8025989049518403" CI_START="0.06152851161981824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="-0.09550143714354266" LOG_CI_START="-1.210923590407145" LOG_EFFECT_SIZE="-0.6532125137753437" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.02169963977109937" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="2.2955846761777328">
<NAME>Histologic relapse</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8025989049518403" CI_START="0.06152851161981824" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.09550143714354266" LOG_CI_START="-1.210923590407145" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="284" O_E="0.0" SE="0.655204494255747" STUDY_ID="STD-Armuzzi-2013" TOTAL_1="11" TOTAL_2="11" VAR="0.4292929292929293" WEIGHT="100.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Direct evidence: probiotics versus placebo</NAME>
<DICH_OUTCOME CHI2="1.9788422138652024" CI_END="1.456220902210816" CI_START="0.5377370349737494" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8849089841456252" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="49.465399869010504" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.1632272605087847" LOG_CI_START="-0.2694300518047233" LOG_EFFECT_SIZE="-0.05310139564796928" METHOD="MH" NO="1" P_CHI2="0.1595127573726659" P_Q="1.0" P_Z="0.6304417945776027" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="58" WEIGHT="100.0" Z="0.48110511500342623">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours probiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2436851960372972" CI_START="0.3774194089610362" EFFECT_SIZE="0.6851211072664359" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.09471046481980322" LOG_CI_START="-0.42317576980983684" LOG_EFFECT_SIZE="-0.16423265249501678" ORDER="67" O_E="0.0" SE="0.3042089377996568" STUDY_ID="STD-Gossum-2007" TOTAL_1="34" TOTAL_2="36" VAR="0.09254307783719547" WEIGHT="76.3652378156195" />
<DICH_DATA CI_END="3.966303686263451" CI_START="0.5905323467616467" EFFECT_SIZE="1.5304347826086957" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.598385963580621" LOG_CI_START="-0.22875630865954477" LOG_EFFECT_SIZE="0.18481482746053815" ORDER="69" O_E="0.0" SE="0.48586746513415496" STUDY_ID="STD-Prantera-2002" TOTAL_1="23" TOTAL_2="22" VAR="0.2360671936758893" WEIGHT="23.634762184380502" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.414365715823831" CI_START="0.0718762581223113" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3188405797101449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.15056172051332412" LOG_CI_START="-1.1434145403434224" LOG_EFFECT_SIZE="-0.4964264099150491" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.13261808912226083" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.00000000000001" Z="1.5038573949784857">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours probiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.414365715823831" CI_START="0.0718762581223113" EFFECT_SIZE="0.3188405797101449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.15056172051332412" LOG_CI_START="-1.1434145403434224" LOG_EFFECT_SIZE="-0.4964264099150491" ORDER="69" O_E="0.0" SE="0.7600880609130471" STUDY_ID="STD-Prantera-2002" TOTAL_1="23" TOTAL_2="22" VAR="0.577733860342556" WEIGHT="100.00000000000001" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.254204675011635" CI_END="1.2462466378213128" CI_START="0.8526810523684085" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0308495984614185" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" I2="52.987687410819504" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.09560399966264439" LOG_CI_START="-0.06921338747204432" LOG_EFFECT_SIZE="0.013195306095300027" METHOD="MH" NO="3" P_CHI2="0.11918220534628066" P_Q="1.0" P_Z="0.7536501177644931" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="108" WEIGHT="100.0" Z="0.3138300535080711">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours probiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4021761464471498" CI_START="0.8598706533697074" EFFECT_SIZE="1.0980392156862746" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.14680257470391733" LOG_CI_START="-0.06556687288738913" LOG_EFFECT_SIZE="0.040617850908264086" ORDER="208" O_E="0.0" SE="0.12474686476085328" STUDY_ID="STD-Gossum-2007" TOTAL_1="34" TOTAL_2="36" VAR="0.015561780267662619" WEIGHT="37.57699404839255" />
<DICH_DATA CI_END="1.138797301493941" CI_START="0.591466185444034" EFFECT_SIZE="0.8207070707070707" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" LOG_CI_END="0.05644642936736627" LOG_CI_START="-0.22807007926064213" LOG_EFFECT_SIZE="-0.08581182494663792" ORDER="679" O_E="0.0" SE="0.16712640554752392" STUDY_ID="STD-Marteau-2006" TOTAL_1="48" TOTAL_2="50" VAR="0.02793123543123544" WEIGHT="46.31338202042779" />
<DICH_DATA CI_END="2.396829318718598" CI_START="0.9117274982500638" EFFECT_SIZE="1.4782608695652173" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.3796371084692334" LOG_CI_START="-0.04013494641990895" LOG_EFFECT_SIZE="0.16975108102466221" ORDER="209" O_E="0.0" SE="0.24657618294706593" STUDY_ID="STD-Prantera-2002" TOTAL_1="23" TOTAL_2="22" VAR="0.06079981399674493" WEIGHT="16.109623931179666" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Direct evidence: purine analogues versus placebo</NAME>
<DICH_OUTCOME CHI2="0.14286148410753863" CI_END="0.9553875459405063" CI_START="0.6854450175949149" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8092376864909054" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="105" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-0.019820424309278214" LOG_CI_START="-0.16402737604996653" LOG_EFFECT_SIZE="-0.09192390017962238" METHOD="MH" NO="1" P_CHI2="0.7054528452257542" P_Q="1.0" P_Z="0.01246372066379699" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="152" WEIGHT="100.00000000000001" Z="2.4987357612896575">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9774821499872784" CI_START="0.6194115500863341" EFFECT_SIZE="0.7781155015197568" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="-0.009891164605045348" LOG_CI_START="-0.20802070067120415" LOG_EFFECT_SIZE="-0.10895593263812474" ORDER="187" O_E="0.0" SE="0.11638227024228266" STUDY_ID="STD-Hanauer-2004" TOTAL_1="47" TOTAL_2="40" VAR="0.013544832826747712" WEIGHT="33.619456366237486" />
<DICH_DATA CI_END="1.0288806036792748" CI_START="0.6615199057753507" EFFECT_SIZE="0.825" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="70" LOG_CI_END="0.012364980037670009" LOG_CI_START="-0.17945708293781995" LOG_EFFECT_SIZE="-0.08354605145007493" ORDER="49" O_E="0.0" SE="0.11267722932632843" STUDY_ID="STD-Mowat-2016" TOTAL_1="128" TOTAL_2="112" VAR="0.012696158008658007" WEIGHT="66.38054363376253" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.751151756414712" CI_START="0.6375796918276304" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9148936170212767" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.7597548275358136" LOG_CI_START="-0.19546552452859875" LOG_EFFECT_SIZE="0.28214465150360746" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.24693175848612858" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="40" WEIGHT="99.99999999999999" Z="1.1578341147831532">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.751151756414712" CI_START="0.6375796918276304" EFFECT_SIZE="1.9148936170212767" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7597548275358136" LOG_CI_START="-0.19546552452859875" LOG_EFFECT_SIZE="0.28214465150360746" ORDER="187" O_E="0.0" SE="0.5611011632196374" STUDY_ID="STD-Hanauer-2004" TOTAL_1="47" TOTAL_2="40" VAR="0.31483451536643026" WEIGHT="99.99999999999999" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10606563627965346" CI_END="3.935687680365247" CI_START="0.2965295323526519" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0802997858672378" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.5950206273417025" LOG_CI_START="-0.527932047328068" LOG_EFFECT_SIZE="0.03354429000681723" METHOD="MH" NO="3" P_CHI2="0.744668632329538" P_Q="1.0" P_Z="0.9067854372525831" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="152" WEIGHT="100.0" Z="0.11709416039222241">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.77078684874297" CI_START="0.12551315121435958" EFFECT_SIZE="0.851063829787234" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7612350333929948" LOG_CI_START="-0.901310766608505" LOG_EFFECT_SIZE="-0.07003786660775507" ORDER="187" O_E="0.0" SE="0.9765876326553183" STUDY_ID="STD-Hanauer-2004" TOTAL_1="47" TOTAL_2="40" VAR="0.9537234042553191" WEIGHT="50.32119914346895" />
<DICH_DATA CI_END="7.714216032234754" CI_START="0.22330930878804534" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8872917968704099" LOG_CI_START="-0.6510931727144208" LOG_EFFECT_SIZE="0.11809931207799448" ORDER="48" O_E="0.0" SE="0.9036549462625443" STUDY_ID="STD-Mowat-2016" TOTAL_1="128" TOTAL_2="112" VAR="0.8165922619047619" WEIGHT="49.678800856531055" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0260090487208346" CI_END="1.304941600195248" CI_START="0.6623301531681536" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9296785304247991" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="50.64187888838048" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.11559107621034125" LOG_CI_START="-0.17892547286123858" LOG_EFFECT_SIZE="-0.03166719832544867" METHOD="MH" NO="4" P_CHI2="0.154626587996042" P_Q="1.0" P_Z="0.6734038667481139" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="152" WEIGHT="100.00000000000001" Z="0.421481023085611">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.751151756414712" CI_START="0.6375796918276304" EFFECT_SIZE="1.9148936170212767" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7597548275358136" LOG_CI_START="-0.19546552452859875" LOG_EFFECT_SIZE="0.28214465150360746" ORDER="187" O_E="0.0" SE="0.5611011632196374" STUDY_ID="STD-Hanauer-2004" TOTAL_1="47" TOTAL_2="40" VAR="0.31483451536643026" WEIGHT="8.993494068120935" />
<DICH_DATA CI_END="1.1901334084146145" CI_START="0.5820790386972774" EFFECT_SIZE="0.8323170731707317" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="41" LOG_CI_END="0.07559564651090468" LOG_CI_START="-0.23501803985275085" LOG_EFFECT_SIZE="-0.07971119667092307" ORDER="46" O_E="0.0" SE="0.18245601693255623" STUDY_ID="STD-Mowat-2016" TOTAL_1="128" TOTAL_2="112" VAR="0.03329019811489324" WEIGHT="91.00650593187908" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1101087386622397" CI_START="0.8109226273164956" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9487951807228916" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="83" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="0.04536552138846392" LOG_CI_START="-0.09102058121733554" LOG_EFFECT_SIZE="-0.02282752991443577" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5117628498147997" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="112" WEIGHT="100.0" Z="0.6560952418681743">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1101087386622397" CI_START="0.8109226273164956" EFFECT_SIZE="0.9487951807228916" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="83" LOG_CI_END="0.04536552138846392" LOG_CI_START="-0.09102058121733554" LOG_EFFECT_SIZE="-0.02282752991443577" ORDER="199" O_E="0.0" SE="0.08011387179274274" STUDY_ID="STD-Mowat-2016" TOTAL_1="128" TOTAL_2="112" VAR="0.00641823245362402" WEIGHT="100.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Direct evidence: purine analogues versus adalimumab</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="77.21979477440601" CI_START="1.6518704018607864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="11.294117647058824" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="1.8877286430733002" LOG_CI_START="0.21797597157725096" LOG_EFFECT_SIZE="1.0528523073252758" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.013447737122041468" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="2.4716865421135146">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="77.21979477440601" CI_START="1.6518704018607866" EFFECT_SIZE="11.294117647058824" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.8877286430733002" LOG_CI_START="0.21797597157725102" LOG_EFFECT_SIZE="1.0528523073252758" ORDER="51" O_E="0.0" SE="0.980820984645806" STUDY_ID="STD-Savarino-2013" TOTAL_1="17" TOTAL_2="16" VAR="0.9620098039215685" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.781522416292998" CI_START="0.8054183728023224" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1978609625668448" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="100.0" ID="CMP-010.02" LOG_CI_END="0.25079129130174427" LOG_CI_START="-0.09397846770641664" LOG_EFFECT_SIZE="0.0784064117976638" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.37268394877686073" Q="1.878308579988185E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="99.99999999999999" Z="0.8914572073985172">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.781522416292998" CI_START="0.8054183728023223" EFFECT_SIZE="1.1978609625668448" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.25079129130174427" LOG_CI_START="-0.09397846770641671" LOG_EFFECT_SIZE="0.0784064117976638" ORDER="51" O_E="0.0" SE="0.20251946307922514" STUDY_ID="STD-Savarino-2013" TOTAL_1="17" TOTAL_2="16" VAR="0.04101413292589763" WEIGHT="99.99999999999999" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="64.88840300542991" CI_START="0.12371667980649814" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="1.8121670856942114" LOG_CI_START="-0.9075717437049504" LOG_EFFECT_SIZE="0.4522976709946303" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5144712519853464" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="0.65189137711187">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.88840300542985" CI_START="0.1237166798064982" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="51" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Savarino-2013" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2092786768971911" CI_END="33.24957325857017" CI_START="2.007687294652936" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="8.170357751277683" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="1.521786075725214" LOG_CI_START="0.3026960706331794" LOG_EFFECT_SIZE="0.9122410731791966" METHOD="MH" NO="4" P_CHI2="0.6473333708635611" P_Q="1.0" P_Z="0.0033541281138740795" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="27" WEIGHT="100.0" Z="2.9332693093721365">
<NAME>Endoscopic relapse</NAME>
<GROUP_LABEL_1>Purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>Adalimumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.32157597345162" CI_START="1.5028186006904503" EFFECT_SIZE="10.352941176470589" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.8532209310963021" LOG_CI_START="0.17690656177544956" LOG_EFFECT_SIZE="1.0150637464358758" ORDER="201" O_E="0.0" SE="0.9846753584290237" STUDY_ID="STD-Savarino-2013" TOTAL_1="17" TOTAL_2="16" VAR="0.9695855614973261" WEIGHT="55.02555366269165" />
<DICH_DATA CI_END="40.36005567001993" CI_START="0.7495034260438386" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6059517566026773" LOG_CI_START="-0.12522637761418984" LOG_EFFECT_SIZE="0.7403626894942439" ORDER="219" O_E="0.0" SE="1.016902605508959" STUDY_ID="STD-Scapa-2015" TOTAL_1="8" TOTAL_2="11" VAR="1.0340909090909092" WEIGHT="44.97444633730834" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Direct evidence: sulfasalazine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.382955232919495" CI_START="0.2428660927622735" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5795454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.1408081219670785" LOG_CI_START="-0.6146331140715429" LOG_EFFECT_SIZE="-0.23691249605223222" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2189514286536981" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.0" Z="1.2293211903145933">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Sulfasalazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sulfasalazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.382955232919495" CI_START="0.2428660927622735" EFFECT_SIZE="0.5795454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.1408081219670785" LOG_CI_START="-0.6146331140715429" LOG_EFFECT_SIZE="-0.23691249605223222" ORDER="42" O_E="0.0" SE="0.44374992154351445" STUDY_ID="STD-Wenckert-1978" TOTAL_1="32" TOTAL_2="34" VAR="0.1969139928698752" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.375471856362067" CI_START="0.014923009514314854" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35353535353535354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.9230092836302773" LOG_CI_START="-1.826143584124826" LOG_EFFECT_SIZE="-0.4515671502472743" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5196565219986269" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.0" Z="0.6438749634237412">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Sulfasalazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sulfasalazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.375471856362063" CI_START="0.014923009514314854" EFFECT_SIZE="0.35353535353535354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9230092836302771" LOG_CI_START="-1.826143584124826" LOG_EFFECT_SIZE="-0.4515671502472743" ORDER="43" O_E="0.0" SE="1.6148660030455182" STUDY_ID="STD-Wenckert-1978" TOTAL_1="32" TOTAL_2="34" VAR="2.6077922077922078" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.375471856362067" CI_START="0.014923009514314854" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35353535353535354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="0.9230092836302773" LOG_CI_START="-1.826143584124826" LOG_EFFECT_SIZE="-0.4515671502472743" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5196565219986269" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.0" Z="0.6438749634237412">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Sulfasalazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sulfasalazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.375471856362063" CI_START="0.014923009514314854" EFFECT_SIZE="0.35353535353535354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9230092836302771" LOG_CI_START="-1.826143584124826" LOG_EFFECT_SIZE="-0.4515671502472743" ORDER="44" O_E="0.0" SE="1.6148660030455182" STUDY_ID="STD-Wenckert-1978" TOTAL_1="32" TOTAL_2="34" VAR="2.6077922077922078" WEIGHT="100.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Direct evidence: sulfasalazine + prednisolone versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.404673634944019" CI_START="0.5688681627966251" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1695906432748537" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.3810561417656002" LOG_CI_START="-0.24498837122194547" LOG_EFFECT_SIZE="0.06803388527182734" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6701160329147153" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="40" WEIGHT="100.0" Z="0.4259887662772769">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Sulfasalazine+ c/steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sulfasalazine+c/s</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.404673634944019" CI_START="0.5688681627966251" EFFECT_SIZE="1.1695906432748537" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.3810561417656002" LOG_CI_START="-0.24498837122194547" LOG_EFFECT_SIZE="0.06803388527182734" ORDER="45" O_E="0.0" SE="0.3677416458992032" STUDY_ID="STD-Bergman-1976" TOTAL_1="57" TOTAL_2="40" VAR="0.13523391812865496" WEIGHT="100.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Direct evidence not in network: clinical relapse</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0810248007236964" CI_START="0.36672005141986624" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6296296296296297" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" I2="0.0" I2_Q="100.0" ID="CMP-013.01" LOG_CI_END="0.03383565759243737" LOG_CI_START="-0.43566534315386407" LOG_EFFECT_SIZE="-0.20091484278071337" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.09345149841360972" Q="4.0514661958864603E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="101" WEIGHT="100.0" Z="1.6774654587904099">
<NAME>4.0 g/d versus 2.4 g/d mesalazine</NAME>
<GROUP_LABEL_1>4.0 g/d</GROUP_LABEL_1>
<GROUP_LABEL_2>2.4 g/d</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 4.0 g/d</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2.4 g/d</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0810248007236964" CI_START="0.36672005141986624" EFFECT_SIZE="0.6296296296296297" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="0.03383565759243737" LOG_CI_START="-0.43566534315386407" LOG_EFFECT_SIZE="-0.20091484278071337" ORDER="32" O_E="0.0" SE="0.27578721190581323" STUDY_ID="STD-Caprilli-2003" TOTAL_1="101" TOTAL_2="101" VAR="0.07605858625078195" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Purine analogues versus placebo</NAME>
<GROUP_LABEL_1>purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.082792234019883" CI_START="0.3252226370326044" EFFECT_SIZE="0.593421052631579" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.03454513227171757" LOG_CI_START="-0.4878192330773791" LOG_EFFECT_SIZE="-0.2266370504028308" ORDER="94" O_E="0.0" SE="0.3068394139513702" STUDY_ID="STD-D_x0027_Haens-2008" TOTAL_1="40" TOTAL_2="41" VAR="0.09415042595402032" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.352519177040945" CI_END="1.3266890152271922" CI_START="0.16075812086325925" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4618181818181819" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="26.06389491734897" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="0.12276913326465222" LOG_CI_START="-0.7938270790132635" LOG_EFFECT_SIZE="-0.3355289728743057" METHOD="MH" NO="3" P_CHI2="0.24483835828258427" P_Q="1.0" P_Z="0.15130766697362547" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="1.4349278205482294">
<NAME>Infliximab versus placebo</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4452230424315222" CI_START="0.02767738876672061" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.159934877280902" LOG_CI_START="-1.5578748859529397" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="35" O_E="0.0" SE="1.009049958219026" STUDY_ID="STD-Regueiro-2009" TOTAL_1="11" TOTAL_2="11" VAR="1.0181818181818183" WEIGHT="56.36363636363637" />
<DICH_DATA CI_END="2.9973039350987856" CI_START="0.21352522595574108" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4767307838677607" LOG_CI_START="-0.6705508098838734" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="84" O_E="0.0" SE="0.6739188873051909" STUDY_ID="STD-Yoshida-2012" TOTAL_1="15" TOTAL_2="16" VAR="0.4541666666666666" WEIGHT="43.63636363636364" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Antibiotics versus placebo</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.780785671924527" CI_START="0.14038747275511293" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2506116527020283" LOG_CI_START="-0.8526716440299906" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="68" O_E="0.0" SE="0.6480740698407861" STUDY_ID="STD-Ma_x00f1_osa-2013" TOTAL_1="25" TOTAL_2="25" VAR="0.42000000000000004" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4722278060122227" CI_START="0.7143242179441472" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0254988913525498" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-013.05" LOG_CI_END="0.1679750160064285" LOG_CI_START="-0.14610462561224685" LOG_EFFECT_SIZE="0.010935195197090835" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.8914428712280593" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="37" WEIGHT="100.00000000000001" Z="0.13647868826999462">
<NAME>5-ASA versus purine analogues</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4722278060122227" CI_START="0.7143242179441474" EFFECT_SIZE="1.0254988913525498" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.1679750160064285" LOG_CI_START="-0.1461046256122468" LOG_EFFECT_SIZE="0.010935195197090835" ORDER="4" O_E="0.0" SE="0.1844919362061101" STUDY_ID="STD-Reinisch-2010" TOTAL_1="41" TOTAL_2="37" VAR="0.034037274525079396" WEIGHT="100.00000000000001" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Direct evidence not in network: adverse events</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.24038594818492" CI_START="0.14927055024491734" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0396039603960396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.8597617168462596" LOG_CI_START="-0.8260258662716684" LOG_EFFECT_SIZE="0.016867925287295513" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9687128774400398" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="105" WEIGHT="100.0" Z="0.039222647489032945">
<NAME>4.0 g/d versus 2.4 g/d mesalazine</NAME>
<GROUP_LABEL_1>Favours 4.0 g/d</GROUP_LABEL_1>
<GROUP_LABEL_2>2.4 g/d</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 4.0 g/d</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2.4 g/d</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.24038594818492" CI_START="0.14927055024491734" EFFECT_SIZE="1.0396039603960396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8597617168462596" LOG_CI_START="-0.8260258662716684" LOG_EFFECT_SIZE="0.016867925287295513" ORDER="33" O_E="0.0" SE="0.9902399711065902" STUDY_ID="STD-Caprilli-2003" TOTAL_1="101" TOTAL_2="105" VAR="0.9805752003771806" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Probiotics versus placebo</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours probiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0302430848318496" CI_START="0.2413403271088743" EFFECT_SIZE="0.8551724137931035" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.48147746882131054" LOG_CI_START="-0.6173701029667902" LOG_EFFECT_SIZE="-0.0679463170727398" ORDER="92" O_E="0.0" SE="0.645468503051536" STUDY_ID="STD-Fedorak-2015" TOTAL_1="58" TOTAL_2="62" VAR="0.4166295884315907" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.56973811041847" CI_END="0.7037270171517318" CI_START="0.33957940503358747" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4888468081009083" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="63" I2="82.71352401486934" I2_Q="100.0" ID="CMP-014.03" LOG_CI_END="-0.1525957754260941" LOG_CI_START="-0.4690586569189296" LOG_EFFECT_SIZE="-0.31082721617251186" METHOD="MH" NO="3" P_CHI2="0.0030737255086057402" P_Q="0.0" P_Z="1.1805961912208964E-4" Q="3.56697199225695E-31" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="183" WEIGHT="100.00000000000001" Z="3.8501207234110413">
<NAME>Infliximab versus placebo</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="133.6642464533259" CI_START="0.400673976362617" EFFECT_SIZE="7.318181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.12601525434829" LOG_CI_START="-0.39720886392900356" LOG_EFFECT_SIZE="0.8644031952096435" ORDER="91" O_E="0.0" SE="1.4821543372369068" STUDY_ID="STD-Fukushima-2018" TOTAL_1="21" TOTAL_2="22" VAR="2.1967814793901748" WEIGHT="0.7767114934043714" />
<DICH_DATA CI_END="1.403410153555011" CI_START="0.5630025226685464" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.147184614288394" LOG_CI_START="-0.24948965918315666" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="36" O_E="0.0" SE="0.23300843180651057" STUDY_ID="STD-Regueiro-2009" TOTAL_1="11" TOTAL_2="11" VAR="0.05429292929292928" WEIGHT="14.298552492216839" />
<DICH_DATA CI_END="0.5748641306901867" CI_START="0.2242344417251675" EFFECT_SIZE="0.35903250188964475" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="54" LOG_CI_END="-0.24043478881325323" LOG_CI_START="-0.6492976803120156" LOG_EFFECT_SIZE="-0.4448662345626344" ORDER="90" O_E="0.0" SE="0.2401680863703271" STUDY_ID="STD-Regueiro-2016" TOTAL_1="147" TOTAL_2="150" VAR="0.0576807097107849" WEIGHT="84.9247360143788" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>5-ASA versus purine analogues</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4215189208995016" CI_START="0.9751456731515866" EFFECT_SIZE="1.177364864864865" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" LOG_CI_END="0.15275264467194727" LOG_CI_START="-0.010930501921767973" LOG_EFFECT_SIZE="0.07091107137508966" ORDER="89" O_E="0.0" SE="0.09614829055379143" STUDY_ID="STD-Reinisch-2010" TOTAL_1="37" TOTAL_2="41" VAR="0.009244493776416299" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Purine analogues versus placebo</NAME>
<GROUP_LABEL_1>purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9742602379496986" CI_START="0.5097041358285309" EFFECT_SIZE="0.7046875" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" LOG_CI_END="-0.011325021756264337" LOG_CI_START="-0.2926818424555889" LOG_EFFECT_SIZE="-0.15200343210592662" ORDER="94" O_E="0.0" SE="0.16527038921750753" STUDY_ID="STD-D_x0027_Haens-2008" TOTAL_1="40" TOTAL_2="41" VAR="0.02731430155210643" WEIGHT="0.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" NO="15">
<NAME>Direct evidence not in network: serious adverse events</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>5-ASA versus purine analogues</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8680164046375541" CI_START="0.0031912796667129114" EFFECT_SIZE="0.05263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.06147206701677475" LOG_CI_START="-2.496035134888883" LOG_EFFECT_SIZE="-1.278753600952829" ORDER="89" O_E="0.0" SE="1.430074397349623" STUDY_ID="STD-Reinisch-2010" TOTAL_1="37" TOTAL_2="41" VAR="2.0451127819548875" WEIGHT="0.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" NO="16">
<NAME>Direct evidence not in network: withdrawal due to adverse events</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.24038594818492" CI_START="0.14927055024491734" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0396039603960396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.8597617168462596" LOG_CI_START="-0.8260258662716684" LOG_EFFECT_SIZE="0.016867925287295513" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9687128774400398" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="105" WEIGHT="100.0" Z="0.039222647489032945">
<NAME>4.0 g/d versus 2.4 g/d mesalazine</NAME>
<GROUP_LABEL_1>4.0 g/d</GROUP_LABEL_1>
<GROUP_LABEL_2>2.4 g/d</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 4.0 g/d</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2.4 g/d</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.24038594818492" CI_START="0.14927055024491734" EFFECT_SIZE="1.0396039603960396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8597617168462596" LOG_CI_START="-0.8260258662716684" LOG_EFFECT_SIZE="0.016867925287295513" ORDER="34" O_E="0.0" SE="0.9902399711065902" STUDY_ID="STD-Caprilli-2003" TOTAL_1="101" TOTAL_2="105" VAR="0.9805752003771806" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Synbiotic versus placebo</NAME>
<GROUP_LABEL_1>Synbiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours synbiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2987130070279735" CI_START="0.33306680636478553" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.3614847532421567" LOG_CI_START="-0.4774686471975302" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="83" O_E="0.0" SE="0.49280538030458115" STUDY_ID="STD-Chermesh-2007" TOTAL_1="20" TOTAL_2="10" VAR="0.24285714285714285" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Probiotics versus placebo</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours probiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.502400170300167" CI_START="0.3262583432758335" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5443657653409251" LOG_CI_START="-0.4864383734702919" LOG_EFFECT_SIZE="0.028963695935316558" ORDER="92" O_E="0.0" SE="0.6054994537004891" STUDY_ID="STD-Fedorak-2015" TOTAL_1="58" TOTAL_2="62" VAR="0.3666295884315907" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.752646602562333" CI_END="0.7238822757411756" CI_START="0.3113730050777872" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4747603600976783" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="55" I2="61.30353731062025" I2_Q="99.99999999999999" ID="CMP-016.04" LOG_CI_END="-0.14033205694254183" LOG_CI_START="-0.5067190419090195" LOG_EFFECT_SIZE="-0.3235255494257807" METHOD="MH" NO="4" P_CHI2="0.051410236806703646" P_Q="0.0" P_Z="5.37455783397365E-4" Q="2.6611244157096637E-31" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="199" WEIGHT="100.0" Z="3.4613588963105753">
<NAME>Infliximab versus placebo</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="133.6642464533259" CI_START="0.400673976362617" EFFECT_SIZE="7.318181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.12601525434829" LOG_CI_START="-0.39720886392900356" LOG_EFFECT_SIZE="0.8644031952096435" ORDER="91" O_E="0.0" SE="1.4821543372369068" STUDY_ID="STD-Fukushima-2018" TOTAL_1="21" TOTAL_2="22" VAR="2.1967814793901748" WEIGHT="0.882020629077523" />
<DICH_DATA CI_END="18.980705815507015" CI_START="0.2107403190840273" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2783123580428297" LOG_CI_START="-0.6762523667148672" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="37" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Regueiro-2009" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="1.8041331049312972" />
<DICH_DATA CI_END="0.5748641306901867" CI_START="0.2242344417251675" EFFECT_SIZE="0.35903250188964475" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="54" LOG_CI_END="-0.24043478881325323" LOG_CI_START="-0.6492976803120156" LOG_EFFECT_SIZE="-0.4448662345626344" ORDER="90" O_E="0.0" SE="0.2401680863703271" STUDY_ID="STD-Regueiro-2016" TOTAL_1="147" TOTAL_2="150" VAR="0.0576807097107849" WEIGHT="96.43911506360024" />
<DICH_DATA CI_END="72.6889396455693" CI_START="0.1397758214597825" EFFECT_SIZE="3.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8614683336055944" LOG_CI_START="-0.8545679467215712" LOG_EFFECT_SIZE="0.5034501934420116" ORDER="84" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Yoshida-2012" TOTAL_1="15" TOTAL_2="16" VAR="2.545343137254902" WEIGHT="0.874731202390932" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-016.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>5-ASA versus purine analogues</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8245467983152825" CI_START="0.014891860374253928" EFFECT_SIZE="0.11081081081081082" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.08378469032472265" LOG_CI_START="-1.8270510443697965" LOG_EFFECT_SIZE="-0.9554178673472595" ORDER="89" O_E="0.0" SE="1.0240032856737005" STUDY_ID="STD-Reinisch-2010" TOTAL_1="37" TOTAL_2="41" VAR="1.048582729070534" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-016.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Purine analogues versus placebo</NAME>
<GROUP_LABEL_1>purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.219364083338482" CI_START="0.18356934698953253" EFFECT_SIZE="0.76875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5077700945618248" LOG_CI_START="-0.7361998369948783" LOG_EFFECT_SIZE="-0.11421487121652682" ORDER="94" O_E="0.0" SE="0.7307140955468795" STUDY_ID="STD-D_x0027_Haens-2008" TOTAL_1="40" TOTAL_2="41" VAR="0.5339430894308942" WEIGHT="0.0" />
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" NO="17">
<NAME>Direct evidence not in network: endoscopic relapse</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.044338774104102" CI_START="0.60202628325793" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7929182748783353" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.018841402744775245" LOG_CI_START="-0.2203845479037852" LOG_EFFECT_SIZE="-0.10077157257950499" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.09869141529980842" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="105" WEIGHT="100.0" Z="1.651231000531776">
<NAME>4.0 g/d versus 2.4 g/d mesalazine</NAME>
<GROUP_LABEL_1>4.0 g/d</GROUP_LABEL_1>
<GROUP_LABEL_2>2.4 g/d</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 4.0 g/d</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2.4 g/d</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.044338774104102" CI_START="0.60202628325793" EFFECT_SIZE="0.7929182748783353" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="59" LOG_CI_END="0.018841402744775245" LOG_CI_START="-0.2203845479037852" LOG_EFFECT_SIZE="-0.10077157257950499" ORDER="34" O_E="0.0" SE="0.14052250759851845" STUDY_ID="STD-Caprilli-2003" TOTAL_1="101" TOTAL_2="105" VAR="0.019746575141775677" WEIGHT="100.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="47" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Probiotics versus placebo</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours probiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1961278544332836" CI_START="0.8441225361153019" EFFECT_SIZE="1.0048275862068965" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="50" LOG_CI_END="0.07777760398946242" LOG_CI_START="-0.07359450491943197" LOG_EFFECT_SIZE="0.0020915495350152273" ORDER="92" O_E="0.0" SE="0.08891672607710828" STUDY_ID="STD-Fedorak-2015" TOTAL_1="58" TOTAL_2="62" VAR="0.007906184176271508" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.214770118960566" CI_END="0.7426846064247529" CI_START="0.5108389988907583" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6159482614940947" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="141" I2="58.418633573425474" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="-0.1291955775844287" LOG_CI_START="-0.29171595487665103" LOG_EFFECT_SIZE="-0.21045576623053988" METHOD="MH" NO="3" P_CHI2="0.0653585335821808" P_Q="1.0" P_Z="3.852386772107015E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="201" WEIGHT="100.0" Z="5.076110811741012">
<NAME>Infliximab versus placebo</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2324840004753363" CI_START="0.5008965134942245" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.09078129018020036" LOG_CI_START="-0.3002519912202264" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="91" O_E="0.0" SE="0.2296948851405713" STUDY_ID="STD-Fukushima-2018" TOTAL_1="21" TOTAL_2="22" VAR="0.05275974025974024" WEIGHT="11.302319163752411" />
<DICH_DATA CI_END="0.7062622144164825" CI_START="0.01634368533393299" EFFECT_SIZE="0.10743801652892562" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.15103402822339748" LOG_CI_START="-1.786650007795829" LOG_EFFECT_SIZE="-0.9688420180096133" ORDER="194" O_E="0.0" SE="0.9607689228305227" STUDY_ID="STD-Regueiro-2009" TOTAL_1="11" TOTAL_2="13" VAR="0.9230769230769229" WEIGHT="7.2924065735371775" />
<DICH_DATA CI_END="0.8341403793979785" CI_START="0.5493075411358495" EFFECT_SIZE="0.6769044251363912" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="101" LOG_CI_END="-0.07876085479682565" LOG_CI_START="-0.2601844387517964" LOG_EFFECT_SIZE="-0.169472646774311" ORDER="90" O_E="0.0" SE="0.10656911127637415" STUDY_ID="STD-Regueiro-2016" TOTAL_1="147" TOTAL_2="150" VAR="0.011356975478236216" WEIGHT="72.30677712483944">
<FOOTNOTE>Endoscopic score</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7846447644970873" CI_START="0.13728327907621504" EFFECT_SIZE="0.3282051282051282" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.10532691871540527" LOG_CI_START="-0.8623823560418563" LOG_EFFECT_SIZE="-0.4838546373786308" ORDER="84" O_E="0.0" SE="0.44469811137041076" STUDY_ID="STD-Yoshida-2012" TOTAL_1="15" TOTAL_2="16" VAR="0.19775641025641028" WEIGHT="9.098497137870964" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-017.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>5-ASA versus purine analogues</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Purine analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8245467983152825" CI_START="0.014891860374253928" EFFECT_SIZE="0.11081081081081082" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.08378469032472265" LOG_CI_START="-1.8270510443697965" LOG_EFFECT_SIZE="-0.9554178673472595" ORDER="89" O_E="0.0" SE="1.0240032856737005" STUDY_ID="STD-Reinisch-2010" TOTAL_1="37" TOTAL_2="41" VAR="1.048582729070534" WEIGHT="0.0" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-017.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Purine analogues versus placebo</NAME>
<GROUP_LABEL_1>purine analogues</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine analogues</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1891665114650487" CI_START="0.48266658217666947" EFFECT_SIZE="0.7576086956521739" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.07524267038597601" LOG_CI_START="-0.3163527688810677" LOG_EFFECT_SIZE="-0.12055504924754584" ORDER="94" O_E="0.0" SE="0.23002509945414845" STUDY_ID="STD-D_x0027_Haens-2008" TOTAL_1="40" TOTAL_2="41" VAR="0.05291154637889089" WEIGHT="0.0" />
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES />
<FEEDBACK />
<APPENDICES />
<EXTENSIONS />
</COCHRANE_REVIEW>
